Bijlani Jeewat sold $107K of KWR

Quaker Chemical (KWR) reported Q2 2026 net sales up 10% year over year, driven by mid- to high single-digit share gains, and adjusted EBITDA margins of 16%. The company cited double-digit volume growth in Asia Pacific, price actions, and $10 million run-rate cost savings. It authorized a $250 million buyback and raised its quarterly dividend about 4%. Outlook: end markets flat to modestly positive in 2H 2026; Q3 gross margin expected near Q2 and above 36% by year-end.

Quaker Houghton (NYSE:KWR) reported Q2 gross margin of 35.5%, down 130 bps sequentially, citing higher raw-material and container costs. GAAP diluted EPS was $1.55 and non-GAAP EPS $2.19. Asia-Pacific sales rose 12% YoY on 10% organic volume. Management expects Q3 gross margin roughly in line with Q2 and full-year adjusted EBITDA growth, while targeting >36% gross margin by year-end.

Q2'26 net sales of $532.6 million, an increase of 10% Y/Y Q2'26 net income of $26.8 million and earnings per diluted share of $1.55 Sales volumes increased 7% Y/Y primarily driven by new business wins across all segments Q2'26 non-GAAP net income of $37.9 million and non-GAAP earnings per diluted share of $2.19, a 28% increase Y/Y Delivered Q2'26 adjusted EBITDA of $85.2 million, a 13% increase Y/Y Increased quarterly dividend by approximately 4.3% and repurchased $24.2 million of shares...

QUAKER CHEMICAL CORP (KWR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 kwr2026q2ex-991.htm EX-99.1 Document Exhibit 99.1 NEWS Contact: John Dalhoff Director, Investor Relations investor@quakerhoughton.com T. 1.610.684.7822 For Release: Immediate QUAKER HOUGHTON ANNOUNCES SECOND QUARTER 2026 RESULTS • Q2’26 net sales of $532.6 million , an

Redmile Group, LLC purchased 400,000 indirectly-held shares of Attovia Therapeutics, Inc. (ATTO) at $17.00 ($6.80M total) on 2026-08-06.

Redmile Group, LLC purchased 200,000 shares of Attovia Therapeutics, Inc. (ATTO) at $17.00 ($3.40M total) on 2026-08-06.